approves the extent to which we achieved each of our corporate and individual goals, as applicable, and, for each named executive officer, the amount of the bonus awarded.
In early 2020, our Compensation Committee approved our 2020 corporate performance goals. These goals were divided into three primary categories that the Compensation Committee determined advanced the Company’s overall corporate strategy: (a) research and development, including advancement of our key assets ATI-450, ATI-1777, and ATI-2138, and certain other preclinical drug candidates (65%), (b) finance and business development, including capital allocation and financing objectives (30%), and (c) other corporate activities, including legal and intellectual property objectives (5%). In early 2021, the Compensation Committee considered each of the 2020 corporate performance goals, as well as individual goals where applicable, and awarded Dr. Walker, Ms. Ali-Jackson and Mr. Ruffo 120%, 115% and 115% of their target bonuses, respectively, for the year ended December 31, 2020. The actual bonus amounts paid are reflected in the “Non-Equity Incentive Plan Compensation” column of the Summary Compensation Table above.
Long-Term Incentives
Our 2012 equity compensation plan (the “2012 Plan”) authorized us to make grants to eligible recipients of non-qualified stock options, incentive stock options and restricted stock awards. All of our awards under this plan were in the form of stock options. Following our initial public offering in October 2015, no further awards may be granted under our 2012 Plan, but all outstanding option awards under that plan will continue to be governed by their existing terms.
In connection with our initial public offering, our Board adopted, and our stockholders approved, the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options within the meaning of Section 422 of the Internal Revenue Code (the “Code”) to our employees and our subsidiaries’ employees, and for the grant of nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to our employees, including our officers, as well as our consultants and directors. Our 2015 Plan also provides for the grant of performance cash awards to our employees, consultants and directors. We have issued stock options and restricted stock units from the 2015 Plan.
In July 2017, the Board adopted the 2017 Inducement Plan. The 2017 Inducement Plan was a non-stockholder approved stock plan adopted pursuant to the “inducement exception” provided under Nasdaq listing rules. The only employees eligible to receive grants of awards under the 2017 Inducement Plan were individuals who satisfied the standards for inducement grants under Nasdaq rules, generally including individuals who were not previously an employee or director of the Company. Under the terms of the 2017 Inducement Plan, we were permitted to grant up to 1,000,000 shares of common stock pursuant to nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock awards. All shares of common stock that were eligible for issuance under the 2017 Inducement Plan after October 1, 2018, including any shares underlying any awards that expire or are otherwise terminated, reacquired to satisfy tax withholding obligations, settled in cash or repurchased by us in the future that would have been eligible for re-issuance under the 2017 Inducement Plan, were retired.
We generally issue equity awards on the grant date determined by our Compensation Committee or, in the case of certain awards, on the grant date determined by our Chief Executive Officer pursuant to authority delegated to him by the Compensation Committee in accordance with the 2015 Plan. In the case of stock options, we set the option exercise price and grant date fair value based on the closing price of our common stock on the Nasdaq Global Select Market on the date of grant.
In accordance with historical practices, in March 2020 Dr. Walker, Ms. Ali-Jackson and Mr. Ruffo were granted an annual equity grant consisting of 73,015, 26,551 and 33,189 restricted stock units, respectively, and stock options to purchase 255,552 shares, 92,928 shares and 116,160 shares, respectively, in each case which vest in four equal installments on March 2, 2021, March 2, 2022, March 2, 2023 and March 2, 2024, subject to the officer’s continuous service as of the applicable vesting date. In March 2021, Dr. Walker, Ms. Ali-Jackson and Mr. Ruffo were granted an annual equity grant consisting of 73,100, 28,400 and 33,200 restricted stock units, respectively, and stock options to purchase 255,800 shares, 99,500 shares and 116,000 shares, respectively, in each case which vest in four equal installments on March 1, 2022, March 1, 2023, March 1, 2024 and March 1, 2025, subject to the officer’s continuous service as of the applicable vesting date.